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Synopsis: Using a multi-institutional database, this study found that for patients with 
functional neuroendocrine tumors, the failure to achieve symptom improvement after 
resection is associated with earlier disease recurrence even when accounting for 
histologic type, presence of genetic syndromes, R1 resection margin, and lymph node 
involvement.  
Abstract:  
Background: The goals of resection of functional neuroendocrine tumors (NETs) are 
two-fold: oncologic benefit and symptom control. The interaction between the two is not 
well understood. 
Methods: All patients with functional NETs of the pancreas, duodenum, and ampulla 
who underwent curative-intent resection between 2000 and 2016 were identified. Using 
Cox regression analysis, factors associated with reduced recurrence-free survival (RFS) 
were identified.  
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Results: 230 patients underwent curative-intent resection. 53% were insulinomas, 35% 
gastrinomas, and 12% were other types. 21% had a known genetic syndrome, 23% had 
lymph node (LN) positivity, 80% underwent an R0 resection, and 14% had no 
postoperative symptom improvement (SI). Factors associated with reduced RFS included 
non-insulinoma histology, presence of a known genetic syndrome, LN positivity, R1 
margin, and lack of SI. On multivariable analysis, only the failure to achieve SI following 
resection was associated with reduced RFS. Considering only those patients with an R0 
resection, failure to achieve SI was associated with worse 3-year RFS compared to 
patients with SI (36% vs 80%; p=0.006).  
Conclusions: Failure to achieve symptomatic improvement after resection of functional 
NETs is associated with worse recurrence-free survival. These patients may benefit from 
short-interval surveillance imaging postoperatively to assess for earlier radiographic 
disease recurrence. 
Introduction  
Neuroendocrine tumors (NETs) consist of a heterogeneous group of tumors with 
distinct molecular, histologic, and clinical features with complex and often challenging 
management strategies.(1) These tumors are traditionally divided as either functional or 
nonfunctional: functional NETs produce peptide hormones which cause symptoms, while 
nonfunctional NETs are typically clinically silent until they produce mass effect or bleed. 
Functional NETs are comprised of several histologic types. In sporadic cases, the most 
common type is insulinoma, followed by gastrinoma and other types including 
glucagonoma, VIPoma, and somatostatinoma.(2) Each type is characterized by a discrete 
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secretory phenotype and a predictable clinical syndrome. (3) The otherwise 
distinguishable clinical syndromes, however, can become muddied when functional 
NETs occur in the background of a hereditary tumor syndrome. These tumor syndromes, 
the most common being multiple endocrine neoplasia-I (MEN-I), provide unique 
challenges in the management of these patients.(4-10) 
For both sporadic and hereditary functional NETs, surgical resection provides the 
only potential for cure in patients with locoregional disease. Although NETs are 
generally indolent tumors, many patients undergo resection to relieve the clinical 
symptoms associated with functional NETs.(11) Aside from insulinomas which are 
commonly treated with enucleation, most functional NETs require a wide oncologic 
resection with regional lymphadenectomy to achieve cure.(12, 13) Curative oncologic 
resection, however, is not always possible, as many patients present with distant disease 
due to the propensity of these tumors to metastasize to the liver. Yet even in the 
metastatic setting, multiple groups have demonstrated that resection of liver metastases, 
cytoreductive surgery, and local ablative therapy may be associated with improved 
survival and alleviate symptoms of functional NETs.(14-16) These findings suggest a 
potential interaction between the relief of clinical symptoms of functional NETs, known 
oncologic parameters, disease recurrence, and survival.  
Little information is available regarding the relationship between the achievement 
of hormone-specific symptom control and oncologic benefit after surgery for functional 
neuroendocrine tumors. The aim of this study is to use a large, multi-institutional 
database to define the association between the failure to achieve symptom improvement 
after surgical resection for functional neuroendocrine tumors and clinical outcomes. We 
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also aimed to determine other clinicopathologic factors associated with worse outcomes 
for functional NETs. Lastly, we aimed to establish the prognostic value of symptom 
improvement compared to other known oncologic parameters.  
Methods 
Patients were identified using the United States Neuroendocrine Tumor Study 
Group (US-NETSG), a collaborative of 8 US-based institutions (Emory University, The 
Ohio State University, Stanford University, Virginia Mason University, Vanderbilt 
University, University of Michigan, University of Wisconsin, and Washington University 
in St. Louis). Institutional Review Board (IRB) approval was obtained at each institution. 
All patients who underwent curative-intent surgical resection of a functional NET of the 
pancreas, duodenum, or ampulla between 2000 and 2016 were included. Functional 
tumor status was defined by clinical and histopathologic diagnoses of insulinoma, 
gastrinoma, glucagonoma, somatostatinoma, or VIPoma. Symptomatic non-functional 
NETs with a carcinoid syndrome were excluded. Patients with genetic tumor syndromes 
were included, specifically MEN-I, Von Hippel-Lindau disease, neurofibromatosis 1, and 
tuberous sclerosis. Final resection status was defined as R0 (complete gross tumor 
clearance with negative microscopic margins), R1 (complete gross tumor clearance with 
positive microscopic margins), and R2 (incomplete gross tumor clearance). Patients with 
mortality less than 30 days after surgery were excluded.  
Data on demographics, perioperative conditions, and histopathology were 
collected. Pathology was reviewed by expert GI pathologists at each institution. Staging 
was based on the American Committee on Cancer (AJCC) 7th edition guidelines. (17) 
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Recurrence-free survival (RFS) data were collected from the electronic medical record. 
Disease-recurrence was defined strictly as the radiographic recurrence of disease.  
The primary aim was to assess the association between clinicopathologic 
variables and decreased RFS. The failure of symptom improvement, defined as the 
patient-reported lack of clinical symptom improvement after surgery, was of particular 
interest. Symptoms were specifically related to the secretory phenotype of the resected 
functional tumor, as recorded in post-operative visit documentation in the electronic 
medical record.  
All statistical analysis was conducted using SPSS 22.0 software (IBM Inc., 
Armonk, NY). Chi-squared analysis was used to compare categorical variables, and 
Student’s t-test was used for continuous variables. Univariate and multivariable Cox 
regression analyses were used to determine the association of the variables of interest 
with reduced RFS. All variables which correlated with reduced RFS at statistical 
significance of p<0.1 on univariate analysis were included in the multivariable model. 
Kaplan-Meier survival plots for RFS were constructed to compare patients with and 
without symptom improvement after surgery. Statistical significance was defined as 
p<0.05.  
Results 
Demographics 
Of 2,181 total patients within the US-NETSG database, 230 patients underwent 
curative-intent resection of a functional NET. Demographic characteristics are listed in 
Table 1. Average age was 52.4 (±15.3) years and 110 (47.8%) patients were male. Forty-
eight (20.9%) patients had functional tumors associated with a hereditary tumor 
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syndrome, the most common being MEN-I. The majority of the functional tumors were 
insulinomas (122, 53%), followed by gastrinomas (80, 34.8%), and glucagonomas (11, 
4.8%). 
Perioperative Data and Pathology  
The most frequent location for a functional NET in this cohort was in the pancreas 
(194, 84.3%), followed by the duodenum (26, 11.3%). Perioperative and pathologic 
characteristics are listed in Table 2. One-hundred and two (44%) patients underwent 
enucleation of their tumors, 26 of whom had lymph node retrieval with enucleation, and 
128 (56%) patients underwent anatomic resection. There was no difference in recurrence-
free survival between patients who underwent enucleation versus those who underwent 
anatomic resection (p=0.152). The majority of patients had well-differentiated tumors 
(181 patients, 78.7%) with a Ki-67 of less than 3% (92, 40%). Final resection status was 
R0 for 184 (80%) patients and R1 for 46 (20%) patients. Radiographic surveillance 
strategies varied among patients with 35 (15%) patients undergoing cross-sectional 
imaging at every 3-4 months, 73 (32%) patients at every 6 months-1 year, 2 (1%) patients 
at greater than once per year, and 120 (52%) patients undergoing no set surveillance 
strategy or an unknown surveillance strategy. Postoperatively, 108 (47%) patients 
experienced symptom improvement, 17 (7.4%) did not experience symptom 
improvement, and 105 (45.7%) of patients had unknown symptom improvement 
following surgery. Median follow-up time was 29.4 months. Of patients with disease 
recurrence, 12 (32.4%) had locoregional recurrence, 19 (51.4%) had distant recurrence, 
and 6 (16.2%) patients had both locoregional and distant recurrences. Seventeen patients 
without symptom improvement after surgery experienced disease recurrence (Table 3).  
This article is protected by copyright. All rights reserved. 
  
A
ut
ho
r 
M
an
us
cr
ip
t 
Relationship between Symptom Improvement and Preoperative and Pathologic Factors 
Patients who experienced symptom improvement after surgery were more likely 
to not have a genetic tumor syndrome (p=0.001), have insulinoma tumor histology 
(p=0.014), and have an R0 resection (p=0.007), as seen in Table 4. Multifocality, tumor 
differentiation, Ki-67 index, lymph node positivity, and lymphovascular/perineural 
invasion status were not associated with symptom improvement after surgery.  
Symptom Improvement and Recurrence-free Survival  
On univariable analysis, factors associated with reduced RFS were non-
insulinoma tumor histology (gastrinoma: HR 2.8, 95% CI 1.3-6.1,p=0.006, other: HR 2.7, 
95% CI 1.0-7.2 p=0.042), having a known genetic tumor syndrome (HR 1.8, 95% CI 0.9-
3.5, p=0.077), lymph node positivity (HR 1.8, 95% CI 0.9-3.6, p=0.080), R1 resection 
margin (HR 2, 95% CI 1.0-3.9, p=0.052) and failure of symptom improvement after 
surgery (HR 3.1, 95% CI 1.3-7.2, p=0.008) (Table 5). Tumor location, multifocality, and 
tumor differentiation were not associated with decreased RFS. On multivariable analysis 
however, only the failure of symptom improvement was associated with decreased RFS 
(HR 4.7, 95% CI 1.3-16.6, p=0.016).  
For this entire cohort, patients without symptom improvement had a lower 3-year 
RFS than patients who did experience symptom improvement (49.9% vs 80.3%, p=0.005, 
Figure 1a). When considering only patients with R0 resections, patients without symptom 
improvement continued to have a decreased 3-year RFS compared to patients with 
symptom improvement after surgery (36% vs 80%, p=0.006, Figure 1b).  
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Discussion 
Functional neuroendocrine tumors are surgically resected for both oncologic 
benefit and for symptom control, but the interaction between the two is not clear. This 
study found that patients who fail to experience hormone-specific symptom improvement 
after surgical resection tend to have worse RFS than those who do experience symptom 
improvement, even in patients who received an R0 resection. When evaluating other 
variables associated with worse RFS, the failure of symptom improvement persisted as 
the only factor associated with decreased RFS when considering resection status, lymph 
node positivity, the presence of a hereditary tumor syndrome and histologic type of 
tumor. Thus, the failure of symptom improvement after resection may serve as an 
important clinical indicator for worse prognosis and earlier radiographic recurrence of 
disease.  
NETs tend to be more indolent tumors with a better prognosis compared to other 
malignancies within the gastrointestinal tract.(18) Compared to nonfunctional NETs, 
functional NETs are described to carry a better prognosis as they are more likely to 
present earlier in their disease course with identifiable clinical manifestations.(19-21) 
Even with generally favorable outcomes, certain subtypes of functional NETs are 
aggressive, particularly those with non-insulinoma histology. Gastrinomas cause clinical 
symptoms leading to significant morbidity, and many patients with gastrinomas have 
metastatic disease at the time of presentation.(2) Even with this more aggressive 
histopathologic tumor type, patients may benefit from surgery with improvement in 
symptom control and increased survival.(22) Patients with functional NETs in the 
background of hereditary tumor syndromes have also been described to have worse 
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prognoses, due to the presence of multifocal tumors which occur earlier in age. Multiple 
groups have previously demonstrated that in well-selected patients, surgical resection can 
both alleviate symptoms and increase survival.(4, 23, 24) Our study confirmed previous 
findings that patients with non-insulinoma histology and genetic tumor syndromes have 
lower RFS. However when examining these variables together in a multivariable model 
with failure of symptom improvement after surgery, only the failure of symptom 
improvement persisted as being associated with decreased RFS.  
In this cohort of functional NETs, symptom control likely serves as a perceptible 
measure for oncologic control. Symptom persistence may represent a manifestation of 
other oncologic parameters, such as micro-metastatic disease. This is supported by a 
mouse study performed by Li et al. in which micrometastases of pancreatic β-cell tumors 
express insulin even at distant sites such as the lung and spleen.(25) In our cohort of 
patients who underwent R0 resections however, there was no radiographic, pathologic or 
surgical evidence which would suggest these patients had residual disease. These findings 
suggest that symptom persistence after surgery may serve as a strong surrogate marker 
for persistence of tumor cells within the body. Although there is no current standard 
adjuvant therapy for patients with functional NETs, as the therapeutic armamentarium 
grows, it is feasible that symptom persistence after surgery may be a reasonable selection 
criterion for patients in future clinical trials. (26, 27) Even more importantly however, 
this study demonstrates that patients with symptom persistence may warrant more 
frequent radiographic surveillance to detect earlier disease recurrence.(28)  
The retrospective design and multi-institutional nature of this study pose certain 
limitations. Capturing complete recurrence data in a retrospective design presented some 
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challenges, as some patients were lost to follow-up. Also, surgical conduct and 
pathologic examination was not standardized across institutions, which may lead to 
variability in reporting. Further, surveillance strategies were not standardized in this 
retrospective study which may impact our recurrence rates and timing. Despite these 
limitations, this study serves as one of the largest in the literature focusing on functional 
neuroendocrine tumors, as well as symptom control after surgery. Furthermore, the multi-
institutional model captures several institutions and patient populations from a diverse set 
of geographic regions in the United States.  
Conclusion  
Patients with functional neuroendocrine tumors who fail to experience hormone-
specific symptom improvement after curative-intent surgical resection have worse 
recurrence-free survival than those patients who do experience symptom improvement. 
The failure of symptom improvement likely serves as a perceptible measure of sub-
radiographic residual disease. Patients who fail to have symptom improvement after 
curative-intent resection may be well-suited to undergo short-interval radiographic 
surveillance in order to detect earlier radiographic recurrence of disease.  
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Figure 
Figure 1:  
Kaplan-Meier plots assessing the association between symptom improvement and 
recurrence-free survival. For all patients within the study cohort (a), the failure to achieve 
postoperative symptom improvement was associated with a significantly reduced 
recurrence-free survival. This remained true when examining only patients with R0 
resection status on final pathologic assessment (b).  
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Table 1: Demographic characteristics of patients with functional neuroendocrine tumors 
within the US- Neuroendocrine Tumor Study Group database.  
Baseline Variable n (%) 
Age (years), mean, ± STD 52.4 ± 15.3 
Male  110 (47.8) 
BMI, mean, ± STD 29.1 ± 6.9 
Race 
 
 White 173 (75.2) 
 Black 21 (9.1) 
 Latino 11 (4.8) 
Functional Status 
 
 Independent  184 (80.0) 
 Partially Dependent 11 (4.8) 
Genetic Syndrome  48 (20.9) 
 MEN-I 41 (17.8) 
 Neurofibromatosis-1  1 (0.4) 
 Other  6 (2.6) 
Type of Functional Tumor  
 Insulinoma 122 (53.0) 
 Gastrinoma 80 (34.8) 
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 Glucagonoma 11 (4.8) 
 VIPoma 10 (4.3) 
 Somatostatinoma 3 (1.3) 
 Other 4 (1.7) 
Abbreviations: MEN-I, multiple endocrine neoplasia type 1.  
 
Table 2: Perioperative and pathologic characteristics of patients with functional 
neuroendocrine tumors within the US- Neuroendocrine Tumor Study Group database. 
Pathologic Variable n (%) 
Operative Intent  
 Curative 230 (100.0) 
Type of Resection  
 Enucleation alone 76 (33.0) 
 Enucleation with lymph node retrieval  26 (11.3) 
 Anatomic Resection 128 (55.7) 
Multifocal Tumors 31 (16.1) 
Tumor Size (cm), median (IQR) 1.7 (1.2-2.5) 
Tumor Location  
 Pancreas 194 (84.3) 
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 Duodenum 26 (11.3) 
 Liver 5 (2.2) 
 Ampulla 5 (2.2) 
# Tumors, median (IQR) 1 (1-1) 
Tumor Differentiation  
 Well 181 (78.7) 
 Moderate 9 (3.9) 
Ki-67  
 <3% 92 (40.0) 
 3-20% 40 (17.4) 
 >20% 3 (1.3) 
 Unknown 113 (43.5) 
LVI 48 (20.9) 
PNI 16 (7.0) 
Lymph Node Positive 52 (22.6) 
# Lymph Nodes Positive, median (IQR) 0 (0-1) 
Final Resection Status   
 R0 184 (80.0) 
 R1  46 (20.0) 
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 Abbreviations: LVI, lymphovascular invasion; PNI, perineural invasion 
  
Postoperative Variable 
Any Complication 
 Clavien-Dindo 1 
 Clavien-Dindo 2 
 Clavien Dindo ≥3 
Symptom Improvement  
 Yes 
 No 
 Unknown 
Reoperation 
Readmission 
Recurrence 
 
n (%) 
118 (51.3) 
26 (11.3) 
33 (14.3) 
59 (25.7) 
 
108 (47.0) 
17 (7.4) 
105 (45.7) 
11 (4.8) 
46 (20.0) 
38 (16.5) 
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Table 3: Preoperative and postoperative characteristics of patients without symptom 
improvement who experienced disease recurrence.  
P
t 
# 
Ag
e 
(yr
s) 
Se
x 
Type of 
Tumor 
Genetic 
Syndro
me 
Type of 
Resecti
on 
Siz
e 
(c
m) 
Tumor 
Locatio
n 
R0/
R1 
Multifoc
al 
Recurre
nce 
Region 
of 
Recurren
ce  
1 59 F VIPoma None Anatomi
c 
1.7 Liver R0 Yes Distant 
2 70 M VIPoma None Anatomi
c 
2 Pancrea
s 
R0 No Distant 
3 47 M Gastrinom
a 
Other Anatomi
c 
9.1 Pancrea
s 
R0 Yes Distant 
4 52 F Gastrinom
a 
None Anatomi
c 
1.3 Pancrea
s 
R0 Yes - 
5 33 M Gastrinom
a 
MEN-1 Anatomi
c 
11.
5 
Pancrea
s 
R0 Yes Distant 
 
6 
45 F Glucagon
oma 
None Anatomi
c 
15.
2 
Pancrea
s 
R0 Yes Locoregio
nal + 
Distant 
7 52 F Insulinom
a 
MEN-1 Anatomi
c 
2.0 Pancrea
s 
R0 No Locoregio
nal 
8 38 M Insulinom
a 
None Anatomi
c 
4.6 Pancrea
s 
R0 No Distant 
9 63 M Insulinom
a 
None Anatomi
c 
12.
9 
Pancrea
s 
R0 No Locoregio
nal + 
Distant 
1
0 
66 F Gastrinom
a 
None Enucleat
ion 
1.8 Pancrea
s 
R1 Yes Locoregio
nal 
1
1 
48 M Gastrinom
a 
MEN-1 Enucleat
ion 
2.0 Pancrea
s 
R1 - Locoregio
nal 
1
2 
44 F Gastrinom
a 
None Enucleat
ion 
1.3 Duoden
um 
R0 Yes Locoregio
nal 
1
3 
73 F Gastrinom
a 
None Enucleat
ion 
5.5 Pancrea
s 
R0 No Distant 
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1
4 
38 F Gastrinom
a 
MEN-1 Enucleat
ion 
1.4 Duoden
um 
- Yes Locoregio
nal 
1
5 
42 M Glucagon
oma 
None Enucleat
ion 
7.5 Pancrea
s 
R0 No Distant 
1
6 
39 F Insulinom
a 
None Enucleat
ion 
1.0 Pancrea
s 
R0 No Distant 
1
7 
91 F Insulinom
a 
None Enucleat
ion 
7.5 Pancrea
s 
R0 Yes Distant 
 
 
Table 4: Relationship between clinicopathologic factors of patients with functional 
neuroendocrine tumors and post-operative symptom improvement.  
 
 Symptom Improvement  
Variable No, n (%) Yes, n (%) p value 
Known Genetic 
Syndrome  9 (52.9%) 16 (14.8%) 0.001 
Type of Functional 
Tumor   0.014 
 Insulinoma 5 (29.4%) 63 (58.3%)  
 Gastrinoma 11 (64.7%) 30 (27.8%)  
 Other 1 (5.9%) 15 (13.9%)  
Multifocal 6 (35.3%) 22 (20.4%) 0.290 
Tumor Location   0.091 
 Pancreas 12 (70.6%) 88 (81.5%)  
 Duodenum 4 (23.5%) 12 (11.1%)  
 Liver 0 (0%) 4 (3.7%)  
 Ampulla 0 (0%) 4 (3.7%)  
Tumor Differentiation   0.601 
This article is protected by copyright. All rights reserved. 
  
A
ut
ho
r 
M
an
us
cr
ip
t 
 Well 13 (100%) 88 (98.9%)   
 Moderate 0 (0%) 1 (1.1%)  
Ki67   0.652 
 <3% 6 (54.5%) 41 (65.1%)  
 3-20% 5 (45.5%) 21 (33.3%)  
 >20% 0 (0%) 1 (1.6%)  
LVI 4 (50.0%) 24 (27.0%) 0.332 
PNI 1 (20.0%) 8 (9.9%) 1.0 
Lymph Node Positive 7 (50.0%) 20 (27.8%) 0.185 
Resection Status   0.007 
 R0 9 (52.9%) 91 (84.3%)  
 R1 8 (47.1%) 17 (15.7%)  
Abbreviations: LVI, lymphovascular invasion; PNI, perineural invasion 
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Table 5: Univariable and multivariable cox regression analysis examining clinical and 
pathologic factors associated with reduced recurrence-free survival in patients with 
functional neuroendocrine tumors.  
  Univariable Multivariable 
Variable  HR 95%CI p-value HR 95%CI p-value 
Type of Functional Tumor           
 Insulinoma Ref -- --  Ref --  --  
 Gastrinoma 2.8 (1.3-6.1) 0.006 1.1 (0.6-2.0) 0.75 
 Other (including 
glucagonoma, 
 somatostatinoma, 
VIPoma)  
2.7 (1.0-7.2) 0.042 --  --   -- 
Known Genetic Syndrome 1.8 (0.9-3.5) 0.077 0.68 (0.2-2.0) 0.49 
Lymph Node Positive 1.8 (0.9-3.6) 0.080 1.6 (0.6-4.6) 0.35 
R1 Resection Margin 2 (1.0-3.9) 0.052 0.45 (0.1-1.8) 0.25 
Failure of Symptom 
Improvement  3.1 (1.3-7.2) 0.008 4.7 (1.3-16.6) 0.016 
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